OncoMatch/Clinical Trials/NCT06598787
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Is NCT06598787 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies BL-B01D1 for for recurrent glioblastoma.
Treatment: BL-B01D1 for — This is an open-label, multicenter, phase II study to evaluate the safety, efficacy, and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with recurrent glioblastoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: standard treatment
Recurrent glioblastoma confirmed by pathology after failure of standard treatment
Cannot have received: chemotherapy, biological therapy, immunotherapy
Chemotherapy, biological therapy, immunotherapy, etc., had been used within 4 weeks or 5 half-lives before the first dose
Cannot have received: small molecule targeted therapy
small molecule targeted therapy had been used within 5 days
Cannot have received: palliative radiotherapy
palliative radiotherapy ... had been used within 2 weeks
Cannot have received: modern Chinese medicine preparations approved by NMPA for anti-tumor treatment
modern Chinese medicine preparations approved by NMPA for anti-tumor treatment had been used within 2 weeks
Lab requirements
Blood counts
No blood transfusion, albumin, colony-stimulating factor, any cell growth factor and/or platelet-raising drugs are allowed within 14 days before the first dose of study drug, and the organ function level must meet the requirements
Cardiac function
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; No blood transfusion, albumin, colony-stimulating factor, any cell growth factor and/or platelet-raising drugs are allowed within 14 days before the first dose of study drug, and the organ function level must meet the requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify